• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Lumos Pharma Inc. (Amendment)

    1/24/23 12:58:31 PM ET
    $LUMO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LUMO alert in real time by email
    SC 13G/A 1 formsc13ga.htm FORM SC 13G/A Regulatory Counsel LLC: Form SC 13G/A - Filed by newsfilecorp.com

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

    Lumos Pharma, Inc.

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    55028X109

    (CUSIP Number)

     

    January 25, 2023

    (Date of Event which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [_]  Rule 13d-1(b)

    [X_]  Rule 13d-1(c)

    [_]  Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    SCHEDULE 13G

    CUSIP No. 55028X109

    1 Names of Reporting Persons

    Daniel Farb
    2 Check the appropriate box if a member of a Group (see instructions)

    (a)  [ ]
    (b)  [ ]
    3 Sec Use Only

     
    4 Citizenship or Place of Organization

    Canada
    Number of
    Shares
    Beneficially
    Owned by Each
    Reporting Person
    With:

     
    5 Sole Voting Power

    760,000
    6 Shared Voting Power

     
    7 Sole Dispositive Power

    760,000
    8 Shared Dispositive Power

     
    9 Aggregate Amount Beneficially Owned by Each Reporting Person

    760,000
    10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    [ ]
    11 Percent of class represented by amount in row (9)

    9.07%
    12 Type of Reporting Person (See Instructions)
     
      IN    

    Page 2 of 5


    Item 1.

    (a) Name of Issuer: Lumos Pharma, Inc.

    (b) Address of Issuer's Principal Executive Offices:

    4200 Marathon Blvd., Suite 200

    Austin, Texas 78756

    Item 2.

    (a) Name of Person Filing: Daniel Farb

    (b) Address of Principal Business Office or, if None, Residence: 

    38 Newbury St., 5th Fl.

    Boston MA 02116

    (c) Citizenship: Canada

    (d) Title and Class of Securities: Common Stock

    (e) CUSIP No.: 55028X109

    Item 3.  If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    (a) [_] Broker or dealer registered under Section 15 of the Act;

    (b) [_] Bank as defined in Section 3(a)(6) of the Act;

    (c) [_] Insurance company as defined in Section 3(a)(19) of the Act;

    (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940;

    (e) [_] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

    (f) [_] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

    (g) [_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

    (h) [_] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

    (i) [_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;

    (j) [_] A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);

    Page 3 of 5


    (k) [_] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

    Item 4. Ownership

    (a) Amount Beneficially Owned:   760,000

    (b) Percent of Class:  9.07%

    (c) Number of shares as to which such person has:

     (i) Sole power to vote or to direct the vote: 760,000

     (ii) Shared power to vote or to direct the vote:

    (iii) Sole power to dispose or to direct the disposition of: 760,000

    (iv) Shared power to dispose or to direct the disposition of:

    Item 5. Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [    ].

    Item 6. Ownership of more than Five Percent on Behalf of Another Person.

    Item 7. Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

    Item 8. Identification and classification of members of the group.

    Item 9. Notice of Dissolution of Group.

    Item 10. Certifications.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Page 4 of 5


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated:  January 24, 2023

    /s/ Scott Pomfret  

    Name/Title. Scott Pomfret, Attorney-in-Fact for the Beneficial Owner*

    *Power of Attorney previously filed with IARD in connection with filer's Form 13H filings.

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative.  If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference.  The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Attention:  Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).

    Page 5 of 5


    Get the next $LUMO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LUMO

    DatePrice TargetRatingAnalyst
    11/4/2021$27.00 → $28.00Buy
    HC Wainwright & Co.
    7/21/2021$34.00 → $27.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $LUMO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors

      Aviceda Therapeutics ("Aviceda"), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment car

      4/9/25 7:00:00 AM ET
      $ANNX
      $LUMO
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures' Acquisition of Lumos Pharma

      AUSTIN, Texas and GREENWICH, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO) ("Lumos Pharma" or the "Company"), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, and Double Point Ventures LLC ("DPV") today announced the successful completion of the previously announced tender offer for Lumos Pharma's shares at a purchase price of (i) $4.25 per share in cash at closing, without interest and less applicable tax withholding and (ii) one contingent value right ("CVR") for each share of common stock outstanding, representing the future right to receive additional contingent cash payments upon the achievement of certain milestone even

      12/12/24 8:47:38 AM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201's Unique Pulsatile Mechanism of Action

      AUSTIN, Texas, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials were presented orally at the 62nd Annual European Society for Paediatric Endocrinology Meeting, or ESPE 2024, held November 16-18, 2024 in Liverpool, UK. "The new analyses and updated data from our Phase 2 OraGrowtH210 and OraGrowtH212 Trials presented at ESPE this week demonstrate sustained growth on LUM-201 in moderate Pediatric Growth Hormone Deficiency (PGHD) to 24 months, as well as the correlation of LUM-201's pulsatile

      11/21/24 9:00:00 AM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LUMO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Lumos Pharma with a new price target

      HC Wainwright & Co. reiterated coverage of Lumos Pharma with a rating of Buy and set a new price target of $28.00 from $27.00 previously

      11/4/21 6:27:17 AM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Lumos Pharma with a new price target

      HC Wainwright & Co. reiterated coverage of Lumos Pharma with a rating of Buy and set a new price target of $27.00 from $34.00 previously

      7/21/21 11:37:35 AM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lumos Pharma upgraded by Stifel with a new price target

      Stifel upgraded Lumos Pharma from Hold to Buy and set a new price target of $24.00 from $4.00 previously

      3/11/21 8:10:40 AM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LUMO
    Financials

    Live finance-specific insights

    See more

    $LUMO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $LUMO
    SEC Filings

    See more
    • Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update

      Following Positive End of Phase 2 Meeting with FDA, Company Continues to Advance Plans for Phase 3 Placebo-Controlled Trial of LUM-201 in Moderate Pediatric Growth Hormone Deficiency Expects to Initiate Phase 3 Trial in Q2 2025 Company to Host Conference Call Today at 4:30PM ET AUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced financial results for the quarter ended June 30, 2024 and provided a clinical programs update. "Following our very positive and productive End of Phase 2 Meeting with the FDA, we've made substantial progress finalizing our proposa

      8/1/24 4:05:00 PM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024

      AUSTIN, Texas, July 23, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report second quarter 2024 financial results after the market close on Thursday, August 1, 2024. The company will host a conference call and webcast at 4:30pm ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks. Conference Call and Webcast Details Date: Thursday, August 1, 2024Time: 4:30pm ETDial-in: 1- 866-652-5200 or 1- 412-317-6060 (International)Conference ID: 10191274 Dial-in registratio

      7/23/24 4:05:00 PM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results

      Outcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial Updated 12 and 24-Month Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials Continue to Show Oral LUM-201 Achieves Significant Increase in Growth from Baseline, Durable Effect to 24 Months Company to Host Conference Call May 15, 2024, at 8:30AM ET AUSTIN, Texas, May 14, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, today announced the outcome from its End-of-Phase 2 meeting with the FDA, provided a clinical programs update, and reported financial results for the quarter ended March 31

      5/14/24 4:15:00 PM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Hawkins Richard J returned 757,562 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - LUMOS PHARMA, INC. (0001126234) (Issuer)

      12/13/24 9:32:39 PM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Zoth Lota S. returned 2,187 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - LUMOS PHARMA, INC. (0001126234) (Issuer)

      12/13/24 9:32:27 PM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Mckew John C. returned 13,153 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - LUMOS PHARMA, INC. (0001126234) (Issuer)

      12/13/24 9:32:17 PM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 15-12G filed by Lumos Pharma Inc.

      15-12G - LUMOS PHARMA, INC. (0001126234) (Filer)

      12/23/24 8:00:07 AM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form AW filed by Lumos Pharma Inc.

      AW - LUMOS PHARMA, INC. (0001126234) (Filer)

      12/13/24 8:10:29 AM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Lumos Pharma Inc.

      EFFECT - LUMOS PHARMA, INC. (0001126234) (Filer)

      12/13/24 12:15:10 AM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LUMO
    Leadership Updates

    Live Leadership Updates

    See more
    • Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors

      Aviceda Therapeutics ("Aviceda"), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment car

      4/9/25 7:00:00 AM ET
      $ANNX
      $LUMO
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lumos Pharma Appoints Pediatric Endocrinologist Experienced in Clinical Research and Pharmaceutical Development, Mark Bach, M.D., Ph.D., to Clinical Scientific Advisory Board

      AUSTIN, Texas, July 26, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that Mark Bach, M.D., Ph.D., accepted his appointment to the Company's Clinical Scientific Advisory Board (CSAB) effective July 15, 2021. Dr. Bach joins the Company's accomplished advisory board comprised of noted pediatric endocrinologists, Peter Clayton, M.D., Ph.D.; Reiko Horikawa, M.D., Ph.D.; George Werther, M.D., Ph.D.; and Chairman, Ron Rosenfeld, M.D. Dr. Bach is currently the Chief Medical Officer for ShouTi Inc., having recently joined from Ascendis Pharma where he served as Senior Vice President, End

      7/26/21 4:18:40 PM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lumos Pharma Announces Retirement of Carl Langren and Names Lori Lawley Chief Financial Officer in Planned Succession

      AUSTIN, Texas, April 20, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced several changes to its executive team as the Company celebrates one year since the close of its merger. After a distinguished 40-year career as an accountant and financial executive, including over 15 successful years with the Company and its predecessor, Chief Financial Officer Carl Langren has announced his plans to retire effective as of July 4, 2021. Mr. Langren has served as CFO of the Company since November 2018. After his departure, Mr. Langren will continue to serve as a consultant to Lumos Pharma for a

      4/20/21 4:05:00 PM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LUMO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Lumos Pharma Inc.

      SC 13G - LUMOS PHARMA, INC. (0001126234) (Subject)

      11/12/24 6:27:22 PM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Lumos Pharma Inc. (Amendment)

      SC 13G/A - LUMOS PHARMA, INC. (0001126234) (Subject)

      2/9/24 7:14:19 PM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Lumos Pharma Inc.

      SC 13G - LUMOS PHARMA, INC. (0001126234) (Subject)

      2/6/24 9:57:23 AM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care